Table 4. Comparison of clinicopathologic characteristics of patients with MET exon 14 skipping and with MET copy number gain in lung adenocarcinomas.
| MET E14 skipping | % | MET copy number gain | % | P | |
|---|---|---|---|---|---|
| Total | 21 | 47 | |||
| Gender | |||||
| Male | 7 | 33.33% | 22 | 46.81% | |
| Female | 14 | 66.67% | 25 | 53.19% | 0.427 |
| Age | |||||
| ≥ 60 y | 17 | 80.95% | 27 | 57.45% | |
| < 60 y | 4 | 19.05% | 20 | 42.55% | 0.052 |
| Smoking status | |||||
| Smoking | 4 | 19.05% | 14 | 29.79% | |
| Never-smoking | 17 | 80.95% | 33 | 70.21% | 0.269 |
| Tumor size | |||||
| < 3 | 13 | 61.90% | 29 | 61.70% | |
| ≥ 3 | 8 | 38.10% | 18 | 38.30% | 1.000 |
| Lymph Node status | |||||
| 0 | 15 | 71.43% | 28 | 59.57% | |
| 1 | 5 | 23.81% | 5 | 10.64% | |
| 2 | 1 | 4.76% | 13 | 27.66% | |
| 3 | 0 | 0.00% | 1 | 2.13% | 0.103 |
| Pathologic stage | |||||
| 0 | 4 | 19.05% | 1 | 2.13% | |
| I | 11 | 52.38% | 23 | 48.94% | |
| II | 5 | 23.81% | 6 | 12.77% | |
| III | 1 | 4.76% | 16 | 34.04% | |
| IV | 0 | 0.00% | 1 | 2.13% | 0.016 |
| Differentiation | |||||
| Well | 6 | 28.57% | 3 | 6.38% | |
| Moderate | 8 | 38.10% | 25 | 53.19% | |
| Poor | 7 | 33.33% | 19 | 40.43% | 0.043 |
| Predominant histology subtype | |||||
| AAH/AIS | 4 | 19.05% | 1 | 2.13% | |
| Lepidic | 4 | 19.05% | 2 | 4.26% | |
| Acinar | 6 | 28.57% | 22 | 46.81% | |
| Papillary | 3 | 14.29% | 4 | 8.51% | |
| Solid | 3 | 14.29% | 11 | 23.40% | |
| Micropapillary | 0 | 0.00% | 1 | 2.13% | |
| IMA | 1 | 4.76% | 6 | 12.77% | 0.046 |
Abbreviations: AAH, Atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ (AIS); IMA, Invasive mucinous adenocarcinoma.